Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
A phase1b/2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Sponsor: BerGenBio ASA
Terminated
Funding was terminated early because research interests were going in a different direction.
Other terminated trials from BerGenBio ASA
Other Cancer of Pancreas trials with similar outcome
A PHASE1/PHASE2 clinical study on Cancer of Pancreas, this trial is terminated or withdrawn. The trial is conducted by BerGenBio ASA and has accumulated 12 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2022 — Dec 2023 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2022 — Oct 2022 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
Nov 2021 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BerGenBio ASA
- Translational Genomics Research Institute
- Triligent International
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .